20Feb 2025
Doravirine Maintains Virologic Control and Reduces Inflammation in Elderly

Doravirine Maintains Virologic Control and Reduces Inflammation in Elderly

The study evaluated the efficacy and safety of doravirine (DOR) in 147 elderly people living with HIV (PLWH) switching to a DOR-based regimen. At 48 weeks, virologic control was maintained in 96.1% of patients. Significant reductions were observed in fasting glycemia (p=0.019), triglycerides (p=0.024), and inflammation markers IL-6 (p=0.019) and hs-CRP (p=0.019). These findings highlight DOR as a safe, effective option with potential anti-inflammatory benefits.

  • #oncology

Like

Save

Share